AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00930787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Strattice Reconstructive Tissue Matrix (Hernia Repair)
Description: Hernia repair will be performed, in an open fashion and defect will be closed or reduced in size using musculofascial centralization procedures to reestablish midline.
Study NCT00930787 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Proceed Surgical Mesh (Hernia repair)
Description: Hernia repair will be performed, in an open fashion and defect will be closed or reduced in size using musculofascial centralization procedures to reestablish midline.
Study NCT02316132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stress
Description: Corticotropin-Releasing Hormone
Study NCT02316132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Saline 0.9%
Study NCT04252807 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: The participants in the control arm will receive the routine visits by LHWs of their respective areas. The LHWs are trained to provide antenatal care and referral, immunization services and support to community mobilization, provision of family planning and basic curative care via door to door visits to the households of their allocated areas.
Study NCT03101670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgotinib
Description: one filgotinib oral tablet q.d.
Study NCT03101670 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: one placebo oral tablet q.d.
Study NCT00933946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACTIC ACID(ND)
Description: Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative for 21 consecutive days.
Study NCT04783168 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care
Study NCT04783168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive usual care
Study NCT04783168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion and Education
Description: Install and use Fitbit app
Study NCT03549624 — intervention group
Intervention type: OTHER
Intervention: Standardised protocol for the perioperative management in patients in need of an acute laparotomy
Description: A standardised protocol for the perioperative management of patients including early start of antibiotics and swift surgical intervention as well as an emphasis on repeated monitoring of physiological parameters pre- and post-operatively.
Study NCT04783168 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Device Usage and Evaluation
Description: Use Fitbit to monitor step count
Study NCT04783168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Use Fitbit to monitor step count
Study NCT04783168 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04783168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04783168 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04783168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05417529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music therapy intervention
Description: Participants did not receive premedication with midazolam 0,02 mg/kg intravenous and received music therapy intervention by a certified music therapist FAMI . Music Treatment consisted of 3 steps:~(1)30 minutes before surgery, music therapist (MTp) engaged the patient in an individual brief conversation (10 min.) to identify preferred musical genre/songs and prepared a customized playlists to listen to during induction; (2)After being monitored in the operating room, patients were prepared to listening to music ; (3)Music listening during anesthesia induction. Anesthesia was the same in both groups. Induction was carried out by fentanyl 3mcg/kg, propofol 2 mg/kg and rocuronium at the dose of 1mg/kg to facilitate intubation
Study NCT05417529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Preparation
Description: Partecipants receive premedication with midazolam 0,02 mg/kg intravenous. Anesthesia was the same in both groups. Induction was carried out by fentanyl 3mcg/kg, propofol 2 mg/kg and rocuronium at the dose of 1mg/kg to facilitate intubation
Study NCT01289782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 150 mg capsule once daily for 12 weeks in addition to PegIFN alpha-2a and RBV for 48 weeks
Study NCT01289782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: 150 mg capsule once daily for 12 weeks in addition to PegIFN alpha-2a and RBV for 24 or 48 weeks
Study NCT04525027 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: intra-abdominal pressure in severe acute pancreatitis
Description: daily intra abdominal pressures in patients admitted to ICU will be measured and noted for intial 5 days and followed up until end outcome
Study NCT03425344 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnostic
Description: No traditionally intervention will be given but participants will be exposed to shoulder- MRI, ultrasound and sonoelastography..
Study NCT01949805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-P-IFN-alpha-2b (AOP2014)
Description: Pegylated interferon alpha 2b given Q2W as SC injection
Study NCT01949805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea
Description: Hydroyurea capsules taken daily po
Study NCT00587730 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GE Attenuation Corrected Hawkeye Camera
Description: GE Hawkeye AC system and 360˚ camera orbit
Study NCT03262051 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CYP phenotyping
Description: Phenotyping using a simplified version of the Geneva cocktail
Study NCT00576654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT00576654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00576654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01289782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon alpha-2a (PegIFN alpha-2a)
Description: One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFN alpha-2a once weekly for up to 48 weeks.
Study NCT01289782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a (PegIFN alpha-2a)
Description: One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFN alpha-2a once weekly for up to 48 weeks.
Study NCT01289782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin (RBV)
Description: 200-mg tablets of RBV (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
Study NCT01289782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: 200-mg tablets of RBV (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
Study NCT02789319 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Blood Glucose Meter Systems
Study NCT01154049 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sm14 antigen plus adjuvant GLA
Description: Healthy adults will receive 3 doses of the vaccine, on days 0, 30 and 60.
Study NCT00492622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate-release omeprazole
Description: Immediate-release omeprazole 40 mg qam for 7 days
Study NCT01087619 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Parathyroid surgery
Description: Parathyroid Surgery (regardless of surgical strategy; i.e., focused operation, unilateral- or bilateral neck exploration)
Study NCT03600103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tech2Check
Description: The intervention uses behaviors to improve HIV adherence and self-care. Investigators will use the Center for Disease Control (CDC) Partnership for Health (PfH) Medication Adherence.The CHN will administer PfH at all home/venue-based encounters, using communication styles that are more receptive to adolescents and young adults. Resources will be provided. At the end of the session, the participant will be able to state/demonstrate: goals of HIV care and adherence, meaning of CD4 and Viral Load (VL) measurements and the significance of their own measurements,signs of complications or problems for which participants need to seek additional care,understanding of optimal self-care.Further, CHNs will also provide tips to stay on schedule with taking their ART and problem-solve adherence barriers.
Study NCT04191733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KINCISE(TM) Surgical Automated System
Description: Uncemented Total Hip Arthroplasty via Anterior Approach with and without the KINCISE(TM) Surgical Automated System
Study NCT04191733 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KINCISE(TM) Surgical Automated System
Description: Uncemented Total Hip Arthroplasty via Anterior Approach with and without the KINCISE(TM) Surgical Automated System
Study NCT02842281 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fructan
Description: Short-chain oligosaccharide primarily composed of fructose polymers
Study NCT02842281 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Polysaccharide produced from starch
Study NCT03159442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8871
Description: Powder for inhalation administered via single dose DPI 300 and 600 µg/inhalation.
Study NCT00492622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delayed-release omeprazole
Description: Delayed-release omeprazole 40 mg qam for 7 days
Study NCT02805699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baofeikang Granule
Description: To observe the efficacy and safety of Baofeikang granules on Combined Pulmonary Fibrosis and Emphysema Treatment.Baofeikang Granules consist of（Codonopsis 30g, Cordyceps fungi powder 12g, ophiopogon root 10g, Schisandra 10g, angelica 15g, Bulbus Fritillariae thunbergii 10g, Sophora flavescens 10g,Forsythia suspensa 12g，Pinellia 10g, saponins thorn 10g, Radix Peucedani 10g）.1 bags,P.O（Oral）twice of each 3 months cycle.
Study NCT02805699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: On the basis of comprehensive treatment of spasmolysis antiasthmatic and anti-inflammatory, expectorant, cough ， give Chinese medicine placebo,1 bags,P.O（Oral）twice of each 3 months cycle.
Study NCT00999752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: 5mg/day with increase to 10 mg/day to reach blood pressure \<140/90
Study NCT00576654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study NCT02939573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Randomized to colchicine 0.6 mg x 2/day
Study NCT02939573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone
Description: Randomized to dapsone 150 mg/day
Study NCT02939573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: Randomized to azathioprine 2 mg/kg/day
Study NCT00615823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Patients were assigned to receive 10 mg of atorvastatin for 6 months (supplied by JiaLin Pharmaceutical Co., Beijing, China). The dose was adjusted to 5mg daily if serum transaminase levels increased by less than three times the upper limit of normal or creatine kinase levels increased to less than five times the upper limit of normal. If serum transaminase and creatine kinase levels remained normal and low-density lipoprotein level greater than 3.4mmol/L after 4 weeks of therapy, the dose of drug was increased to 20mg once daily.
Study NCT00615823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients were assigned to receive 10 mg of placebo for 6 months (supplied by JiaLin Pharmaceutical Co., Beijing, China). The dose was adjusted to 5mg daily if serum transaminase levels increased by less than three times the upper limit of normal or creatine kinase levels increased to less than five times the upper limit of normal. If serum transaminase and creatine kinase levels remained normal and low-density lipoprotein level greater than 3.4mmol/L after 4 weeks of therapy, the dose of drug was increased to 20mg once daily.
Study NCT00749658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Form: tablet, Dosage, Frequency, Duration: Days 1-3, 150 mg, q.d., Days 4-11, 150 mg, b.i.d.
Study NCT00749658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Form: tablet, Dosage, Frequency, Duration: Days 1-3, .5 mg, q.d., Days 4-7, .5 mg, b.i.d., Days 8-11, 1 mg, b.i.d.
Study NCT02179788 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Mothers will be instructed to thoroughly empty their breasts at least 8 times per 24 hours by breastfeeding, followed by breast expression with a combination of hand -expression and the use of a hospital-grade electric breast pump (provided by study).
Study NCT02179788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Mothers will be instructed to thoroughly empty their breasts at least 8 times per 24 hours by breastfeeding, followed by breast expression with a combination of hand -expression and the use of a hospital-grade electric breast pump (provided by study).
Study NCT02179788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The metformin arm will be consuming Glucophage XR (metformin hydrochloride extended release, 750 or 500 mg, encapsulated in #00 opaque capsules for 4 weeks according to the following schedule:~* Days 1-7, take one 750 mg capsule with evening meal (750 mg/day)~* Days 8-14, take three 500 mg capsule with evening meal (1500 mg/day)~* Days 14-28 (or through completion of post-intervention data collection), take four 500 mg capsules with evening meal (2000 mg/day)~Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator.~The trial duration is 28 days (with a +/- 3 day cushion)
Study NCT02179788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo arm will be consuming methylcellulose USP Powder encapsulated in #00 opaque capsules (supplied by PCCA, Houston TX) for 4 weeks according to the following schedule:~* Days 1-7, take 1 capsule with evening meal~* Days 8-14, take 3 capsules with evening meal~* Days 14-28 (or through completion of post-intervention data collection), take four capsules with evening meal~Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator.
Study NCT03391505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small-sided soccer game
Description: The small-sided soccer game consists of a single bout (two times ten minutes) of small-sided soccer game (3v3) interspersed with a five minutes break.
Study NCT03391505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking soccer game
Description: The walking soccer game consists of a single bout (two times ten minutes) of small-sided walking soccer game (3v3) interspersed with a five minutes break.
Study NCT03391505 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Rest group watching soccer
Description: The rest group watching soccer consists of watching a soccer game on a laptop (two times ten minutes) interspersed with a five minutes break.
Study NCT03698357 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interactive video balance-based exercise
Description: Interactive video balance-based exercise :10 minutes of warm up exercise, 30 minutes of Interactive video balance-based exercise and 5 minutes of cool down exercise.
Study NCT03698357 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: conventional physiotherapy: 10 minutes of warm up exercise, 30 minutes conventional physiotherapy and 5 minutes of cool down exercise. Conventional physiotherapy contains rolling, sitting, balance exercise, standing, overground walking, facilitation of the paretic limbs, and so on.
Study NCT04468880 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Group (A1 → A2)
Description: Before each start of consumption of the products under study, a wash-out period of 2 weeks (no consumption of milk) must be observed by the subjects.~25 subjects will consume A1A2 milk for 2 weeks (period 1), then they will consume A2A2 milk for 2 weeks (period 2).~During each consumption period, various questionnaires will be completed by the subjects: frequency and consistency of stool, analog visual scales on digestive comfort and dietary surveys. Stool collections will also be carried out.
Study NCT00999752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 25 mg/day
Study NCT02795598 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single injection supraclavicular nerve block
Description: The ultrasound probe will be applied in a sterile fashion in the supraclavicular fossa to obtain a short-axis view of the subclavian artery. A 22G, 50mm Echogenic Stimuplex needle will be advanced in-plane with respect to the image, and the needle tip will be advanced to the junction of the first rib and subclavian artery. Ultrasound cineloops will be kept of all nerve block procedures.~30 milliliters of mepivacaine 1.5% will be injected incrementally in 5ml boluses at this location looking for spread of local anesthetic under and medial to the subclavian artery. The needle may be slightly repositioned to improve the distribution of the injectate at the discretion of the attending anesthesiologist.
Study NCT02795598 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double injection supraclavicular nerve block
Description: The ultrasound probe will be applied in a sterile fashion in the supraclavicular fossa to obtain a short-axis view of the subclavian artery. A 22G, 50mm Echogenic Stimuplex needle will be advanced in-plane with respect to the image, and the needle tip will be advanced to the junction of the first rib and subclavian artery. Ultrasound cineloops will be kept of all nerve block procedures.~15 milliliters of mepivacaine 1.5% will be injected incrementally at the same, above-mentioned location. The needle will then be redirected to the superolateral aspect of the brachial plexus, and an additional 15ml will be injected here. Again, the needle may slightly repositioned at the discretion of the attending anesthesiologist in order to obtain adequate spread.
Study NCT04468880 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Group (A2 → A1)
Description: Before each start of consumption of the products under study, a wash-out period of 2 weeks (no consumption of milk) must be observed by the subjects.~25 subjects will consume A2A2 milk for 2 weeks (period 1), then they will consume A1A2 milk for 2 weeks (period 2).~During each consumption period, various questionnaires will be completed by the subjects: frequency and consistency of stool, analog visual scales on digestive comfort and dietary surveys. Stool collections will also be carried out.
Study NCT03676634 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rBV A/B
Description: Recombinant Botulinum Vaccine A/B, rBV A/B
Study NCT04722133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HERZUMA+mFOLFOX
Description: Herzuma (Trastuzumab-pkrb) 4mg/kg after 6mg/kg loading D1 5FU 400mg/m2 bolus+2400mg/m2 infusion for 46 hrs D1 Leucovorin 200mg/m2 D1 Oxaliplatin 85mg/m2 D1 every 2 weeks
Study NCT01703754 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Ad-RTS-hIL-12 and Veledimex
Description: Oral activator ligand with adenoviral vector injection of cancer lesions
Study NCT01703754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifosfamide
Description: Small molecule chemotherapy, IV administration
Study NCT01953185 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham manual diaphragm release technique
Description: For this group, light touch at the same anatomical points was done without exerting pressure or traction. Positioning and duration were identical to the IG to perform the sham protocol (Licciardone \& Russo, 2006).